MetaStat 

MetaStat, Inc. is a precision medicine company focused on creating advanced therapeutic and diagnostic solutions for cancer patients. The company's primary research and development efforts target the MENA pathway, encompassing both novel drug candidates and specialized companion diagnostic tests. Their extensive diagnostic pipeline includes the MENA diagnostic assay, a tissue-based quantitative immunofluorescence test that measures the expression of a specific pro-metastatic MENA protein splice-variant. They also offer companion diagnostics designed to predict patient responses to RTK inhibitor and anti-microtubule drug therapies. Additionally, MetaStat is developing a liquid blood-based biopsy to improve cancer diagnosis and personalize patient management, along with the MetaSite Breast assay, an immunohistochemistry test that quantifies micro-anatomical intravasation at blood vessels within the tumor microenvironment. A prognostic diagnostic aimed at forecasting the risk of cancer metastasis further rounds out their offerings. On the therapeutic side, MetaStat's strategies target a crucial metastatic pathway in solid tumors, a pathway known to drive drug resistance and the aggressive dissemination of cancer. The company is based in Boston, Massachusetts.